[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344392-105":59,"doc-detail-344392-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","generic-protocols-for-analytical-validation-of-tumor-informed-circulating-tumor-dna-assays-for-molecular-residual-disease-the-blood-proling-atlas-in-cancers-molecular-residual-disease-analytical-validation-working-group-consensus-recommendation","Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Proﬁling Atlas in Cancer’s Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation","","Circulating tumor DNA (ctDNA) in patients signals post-treatment molecular residual disease (MRD), but ctDNA-based MRD detection tests require aligned analytical validation (AV) criteria. The Blood Proﬁling Atlas in Cancer (BLOODPAC) MRD AV Working Group assessed existing protocols to create standardized guidance for tumor-informed assays. Protocols cover objectives, best-practice study design, statistical analysis, and example data presentation in the FDA CDRH format. Biostatisticians defined minimal test requirements and sample size, and the protocols support FDA presubmission review and reviewer streamlining while remaining adaptable across assay technologies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/generic-protocols-for-analytical-validation-of-tumor-informed-circulating-tumor-dna-assays-for-molecular-residual-disease-the-blood-proling-atlas-in-cancers-molecular-residual-disease-analytical-validation-working-group-consensus-recommendation/344392/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/generic-protocols-for-analytical-validation-of-tumor-informed-circulating-tumor-dna-assays-for-molecular-residual-disease-the-blood-proling-atlas-in-cancers-molecular-residual-disease-analytical-validation-working-group-consensus-recommendation/344392.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the BLOODPAC generic protocols for tumor-informed ctDNA MRD testing?","Question",{"text":112,"@type":113},"To provide a standardized baseline of analytical validation protocols that can be adapted across tumor-informed MRD assays, supporting consistent presubmission interactions with the FDA.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which elements did the MRD AV Working Group evaluate when developing the consensus protocols?",{"text":117,"@type":113},"Existing protocols were evaluated across topics relevant to AV, including study design aligned to best practices, statistical analysis, and protocol components structured in the FDA Center for Devices and Radiological Health format.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the protocols help test developers during FDA presubmission review?",{"text":121,"@type":113},"They are designed to optimize presubmission reviews by enabling productive meetings and allowing FDA reviewers to streamline feedback, while encouraging developers to communicate directly for method-specific details.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344392,1790131150,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Special Articles  \nGeneric Protocols for Analytical Validation of  \nTumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Proﬁling Atlas in Cancer’s Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation  \nJonathan Baden, MS1; Cheng-Ho Jimmy Lin, MD, PhD, MHS2; Andrew T. Anfora, PhD3  ; Jonathan Beer, MBA1; Karl Bisselou, PhD4  ; Jennifer Bungo, BS5; Adam S. Corner, BSc6; Tyler Danek, MS7  ; Jennifer Dickey, PhD8; James H. Godsey, PhD9;  \nDonald J. Johann, MD, MSc, FACP10  ; Gregory Jones, BS, BA11  ; George Karlin-Neumann, PhD12  ; Jessica L. Larson, PhD13  ;  \nJerry S.H. Lee, PhD14  ; Li Liu, PhD15  ; Dorys Lopez Ramos, PhD16; David Merriam, MS3; Melanie Palomares, MD, MS5  ; Carol E. Pena, PhD17; Jessica Rathbun, PhD7; Kate Rhodes, PhD18; Jaime E. Connolly Rohrbach, PhD19; Banu Saritas-Yildirim, PhD15; Mark Sausen, PhD8  ;  \nShile Zhang, PhD20; and Lauren C. Leiman, MBA16   \nDOI [https://doi.org/10.1200/PO-25-00267](https://doi.org/10.1200/PO-25-00267)  \nABSTRACT  \nThe presence of circulating tumor DNA (ctDNA) in patients indicates post-treatment molecular residual disease (MRD) . Given the complexity of ctDNA-based MRD detection tests, consensus on analytical validation (AV) criteria is needed. To address this, the Blood Proﬁling Atlas in Cancer (BLOODPAC) Consortium’s MRD AV Working Group evaluated existing protocols to develop standardized guidance for tumor-informed assays. Protocols pertaining to blood collection tube types, quantitative output, tissue processing, tumor or matched normal sequencing, software, and clinical validation were considered out of scope. After alignment on objectives and assumptions, study designs on the basis of best practices in the ﬁeld, available assay validation guidance documents, and unique performance challenges for tumorinformed MRD assays were authored. Each protocol contains introduction, experimental design, statistical analysis, and an example data presentation per the US Food and Drug Administration (FDA) Center for Devices and Radiological Health standard format. Biostatisticians were consulted to deﬁne minimal test requirements, sample size, and appropriate statistical analyses. The protocols were submitted to the FDA via the presubmission process for formal written feedback followed by a meeting. BLOODPAC’s generic protocols for the AV of tumor-informed ctDNA assays for MRD are designed to provide test developers with a core baseline of standardized AV protocols such that methods described can be adapted and applied for any tumor-informed MRD assay irrespective of technology, panel design algorithm, or workﬂow component. These protocols aim to optimize test developers’ presubmission reviews with the FDA, ensuring productive meetings while enabling reviewers to streamline feedback. As always, test developers are encouraged to communicate with FDA directly around their particular AV methods.  \nACCOMPANYING CONTENT  \n Protocol  \nAccepted November 17, 2025 Published January 14, 2026  \nJCO Precis Oncol 10:e2500267 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nIntroduction  \nCirculating tumor DNA (ctDNA) has garnered considerable interest as a promising biomarker in oncology.1 Its minimally invasive testing nature permits genomic proﬁling of tumors through blood samples, offering a host of advantages over conventional tissue biopsies, including reduced harm to patients compared with invasive test methods and increased accessibility. The latter is particularly valuable in cases when tissue biopsies are challenging to obtain. These characteristics make ctDNA an important tool for detection of treatment efﬁcacy and disease monitoring.  \nUnlike traditional biopsies that focus on a localized specimen, ctDNA reﬂects the genetic diversity of the entire tumor across different anatomic sites within an individual. This broader perspective helps understan","cbCailhYaz1StiNi","https://ap.wps.com/l/cbCailhYaz1StiNi","pdf",2866953,13,"English","# Abstract\n## Introduction\n## BLOODPAC and MRD Analytical Validation Working Group\n## Purpose of the Generic Protocols","[{\"question\":\"What is the main goal of the BLOODPAC generic protocols for tumor-informed ctDNA MRD testing?\",\"answer\":\"To provide a standardized baseline of analytical validation protocols that can be adapted across tumor-informed MRD assays, supporting consistent presubmission interactions with the FDA.\"},{\"question\":\"Which elements did the MRD AV Working Group evaluate when developing the consensus protocols?\",\"answer\":\"Existing protocols were evaluated across topics relevant to AV, including study design aligned to best practices, statistical analysis, and protocol components structured in the FDA Center for Devices and Radiological Health format.\"},{\"question\":\"How do the protocols help test developers during FDA presubmission review?\",\"answer\":\"They are designed to optimize presubmission reviews by enabling productive meetings and allowing FDA reviewers to streamline feedback, while encouraging developers to communicate directly for method-specific details.\"}]","Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Proﬁling Atlas in Cancer’s Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation | PDF",1790053576,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/448cf2715601eac79cb1095ec91eb64e.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27a824075b4d0476c6ab51c30b9ab2ab.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0e35f5d5454f4dc0e8d4126e0965481.webp",981,732,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dcb109ac9aef07a1b8ae5be59c3c914d.webp",980,731]